Additional analysis from BELLE-2 and BELLE-3 trials using the BEAMing PCR assay showed a similar concordance of PIK3CA mutation status between circulating tumor (ct)DNA and tumor tissue analysis (77% and 83%, respectively) [30,31]. Here, PIK3CA is linked to neoplasm.